Several weight-loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.
Read more...
Hence then, the article about hims hers zealand and roche why these weight loss drug stocks are down today was published today ( ) and is available on Quartz ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hims & Hers, Zealand, and Roche — why these weight loss drug stocks are down today )
Also on site :
- Zhou Jianjun, de Huawei : concevoir une solution AIDC connectée au réseau pour optimiser le rendement token/watt
- Trip.Biz Launches Agent ONE, an AI Suite Transforming Business Travel -- Cutting Booking Time by 90% for Travellers and Simplifying Oversight for Travel Managers
- Crypto Options Approach Half of Bitcoin Derivatives Market as Bybit Captures 28% of Tracked Volume, Glassnode Report Finds
